List of Excipients in Branded Drug MIRCERA

« Back to Dashboard

MIRCERA Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 22, 2026

MIRCERA is Roche’s long-acting erythropoiesis-stimulating agent, containing methoxy polyethylene glycol-epoetin beta, also called pegylated epoetin beta. Its commercial formulation uses a compact excipient system designed for protein stability, low-volume subcutaneous or intravenous delivery, and refrigerated ready-to-use presentation. The strongest commercial opportunities are in biosimilar development, injectable excipient supply, prefilled-device manufacturing, analytical comparability, and differentiated renal-anemia delivery platforms.

What is MIRCERA and how is it formulated?

MIRCERA is a chemically modified recombinant erythropoietin used to treat anemia associated with chronic kidney disease. The active molecule is epoetin beta covalently linked to a single polyethylene glycol chain. The modification extends systemic exposure compared with conventional epoetin products and supports less frequent administration.[1][2]

MIRCERA formulation composition

Public product information identifies the following excipients in the ready-to-use injectable formulation:

Formulation component	Functional role
Polysorbate 20	Surfactant that limits protein adsorption and interface-driven aggregation
Sodium phosphate monobasic monohydrate	Buffering agent
Sodium sulfate	Tonicity and formulation-supporting salt
L-methionine	Oxidation-control excipient and protein stabilizer
Phenoxyethanol	Preservative in applicable presentations
Water for injection	Vehicle

MIRCERA is supplied as a sterile solution in prefilled syringes and, in some markets, other single-dose presentations. European strengths include 30, 50, 75, 100, 120, 150, 200 and 250 micrograms per 0.3 mL.[1] The U.S. presentation and labeling should be assessed separately because strength availability, device configuration and preservative status can vary by market.[2]

The formulation is generally maintained at an acidic pH, approximately pH 6, with refrigerated storage. The combination of low fill volume, protein-sensitive surfactant selection and oxidation-control chemistry places meaningful constraints on substitute excipients.

What excipient strategy does MIRCERA use?

MIRCERA’s excipient strategy addresses four formulation risks: aggregation, adsorption, oxidation and product-device compatibility.

Why polysorbate 20 is commercially important

Polysorbate 20 protects the pegylated erythropoietin molecule against agitation and contact with air-liquid or container-liquid interfaces. This is important for prefilled syringes, which are exposed to transport vibration, filling operations and injection-device contact surfaces.

Polysorbate 20 also creates a material and analytical-control burden. The excipient can undergo hydrolysis and oxidation, producing degradation species that may affect protein stability or generate subvisible particles. A biosimilar developer cannot treat polysorbate 20 as a simple inactive ingredient. It must control:

• Peroxide content
• Fatty-acid composition
• Hydrolysis products
• Micelle behavior
• Interaction with silicone oil and elastomers
• Effects on aggregation and potency

This creates an opportunity for high-purity polysorbate suppliers that can provide pharmaceutical-grade material with tighter peroxide and degradation specifications.

Why L-methionine matters

L-methionine is commonly used as an oxidation scavenger in protein formulations. It can reduce oxidative stress affecting vulnerable amino-acid residues and may protect biological activity during storage.

For MIRCERA-type products, L-methionine offers a lower-complexity alternative to more aggressive antioxidant systems. The commercial opportunity is strongest for suppliers able to deliver consistent low-bioburden, low-endotoxin material with tight control of trace metals and oxidation-related impurities.

Why sodium phosphate and sodium sulfate are relevant

The phosphate system helps maintain pH. Sodium sulfate contributes to ionic strength and tonicity. These salts also affect protein solubility, viscosity and aggregation behavior.

Formulation developers considering alternative buffers must assess the complete protein-excipient system rather than replacing individual ingredients in isolation. A change from phosphate to histidine, citrate or another buffer can alter:

• Protein charge distribution
• Subvisible particle formation
• Osmolality
• Container interaction
• Syringe injection force
• Long-term potency

The commercial value lies in formulation packages that preserve product quality while improving manufacturability or reducing dependence on a single excipient supplier.

Why phenoxyethanol creates market segmentation

Phenoxyethanol is a preservative used in certain injectable presentations. Its inclusion can support multidose or specific container configurations, but it also introduces compatibility and regulatory considerations.

A preservative-containing presentation may not be interchangeable with a preservative-free product for all patients or markets. Preservative selection affects extractables and leachables, local tolerability, container closure systems and regulatory comparability. This creates a niche for preservative-free, single-use delivery systems that maintain stability without antimicrobial additives.

What formulations are protected by MIRCERA-related intellectual property?

MIRCERA-related intellectual property can be divided into four categories:

1. The pegylated epoetin beta molecule.
2. Methods for preparing or chemically modifying erythropoietin.
3. Stable aqueous formulations containing the modified protein.
4. Delivery presentations, including prefilled syringes and dosing regimens.

The principal commercial barrier is unlikely to be one excipient patent alone. Biosimilar developers must address the combined risk of molecule, manufacturing process, formulation, device and regulatory comparability.

Public FDA materials classify MIRCERA as a biological product rather than a small-molecule drug listed in the Orange Book. Its relevant reference-product and biosimilar information is therefore associated with the Purple Book framework, not conventional Orange Book paragraph IV certification.[3]

Does MIRCERA have Orange Book listings?

No conventional Orange Book strategy applies to MIRCERA as it does to small-molecule products. A biosimilar applicant generally relies on the Biologics Price Competition and Innovation Act pathway under section 351(k) of the Public Health Service Act. Patent certifications and litigation timing therefore differ from an ANDA-based paragraph IV challenge.[3][4]

What is the patent expiration position for MIRCERA?

Patent expiration must be assessed patent by patent and jurisdiction by jurisdiction. Relevant rights may include composition, conjugation chemistry, manufacturing, formulation and use claims. The biologic’s regulatory exclusivity period is separate from patent term.

MIRCERA was approved in the United States in 2007.[2] The reference product’s 12-year U.S. reference-product exclusivity period has therefore elapsed. That does not eliminate formulation, process, device or method-of-use patent risk. A biosimilar applicant must conduct a current patent-and-litigation review before selecting a launch date.

When does MIRCERA lose exclusivity?

MIRCERA’s core U.S. biologic reference-product exclusivity is no longer the primary barrier to market entry. The relevant remaining barriers are:

Barrier	Commercial effect
Active formulation patents	May delay or constrain a biosimilar launch
Process patents	Can force an alternative manufacturing route
Conjugation patents	May affect molecule design or production
Device patents	Can require a different syringe or injector
Method-of-use patents	May affect labeled indications and substitution strategy
Regulatory exclusivity outside the U.S.	Can differ by region
Manufacturing validation	Often becomes the practical launch bottleneck

The European Union has no single Orange Book equivalent. Patent status must be evaluated through national registers, the European Patent Office and litigation records in relevant member states. A European biosimilar can face country-specific enforcement even when a corresponding European patent has been revoked or limited elsewhere.

Which companies are challenging MIRCERA?

The relevant competitive field includes:

• Biosimilar erythropoietin developers
• Manufacturers of pegylated erythropoietin products
• Conventional epoetin suppliers
• Dialysis-focused injectable manufacturers
• Contract development and manufacturing organizations
• Prefilled-syringe and autoinjector suppliers

A direct MIRCERA biosimilar requires more than an epoetin alfa or epoetin beta product. The applicant must demonstrate similarity to the pegylated reference molecule, including structural characterization of the conjugate, pharmacokinetics, pharmacodynamics, immunogenicity and clinical or scientific justification under the applicable regulatory pathway.

Conventional epoetins remain indirect competitors. Their shorter dosing intervals can be offset by lower acquisition cost, established dialysis contracts and broad formulary access. Long-acting products compete on administration frequency, clinic workload and adherence rather than on excipient composition alone.

What generic entry risks exist for MIRCERA?

MIRCERA faces biosimilar rather than conventional generic-entry risk.

Direct biosimilar risk

A direct biosimilar could compete on:

• Lower acquisition price
• Hospital and dialysis-center tenders
• Contracting with renal-care networks
• Alternative syringe suppliers
• Regional launches after patent resolution

The most credible launch strategy would use a formulation that matches the reference product closely enough to minimize clinical and regulatory divergence. A highly differentiated excipient system may create additional analytical and regulatory work.

Substitution risk from other erythropoiesis-stimulating agents

MIRCERA also faces substitution by epoetin alfa, epoetin beta, darbepoetin alfa and newer anemia therapies. Hypoxia-inducible factor prolyl hydroxylase inhibitors can compete through oral administration, although their safety profiles, reimbursement status and use restrictions differ by jurisdiction.

MIRCERA’s commercial position is strongest where reduced injection frequency has measurable value to dialysis providers. Its position is weaker where drug acquisition cost dominates and treatment is already integrated into routine dialysis sessions.

How strong is the MIRCERA patent estate?

The patent estate should be rated as layered rather than dependent on excipients alone.

Patent layer	Strength assessment
Pegylated epoetin composition	Historically central; scope depends on remaining claims and jurisdiction
Conjugation and manufacturing process	Potentially significant because process substitution can be difficult
Aqueous formulation	Moderate strategic value if claims cover specific stabilizer combinations
Prefilled syringe or container	Relevant to device and presentation competition
Dosing and chronic kidney disease use	Potentially important but vulnerable to label and claim-scope limitations
Excipient-specific claims	Usually narrow and easier to design around than molecule claims

The formulation strategy can still create a practical barrier after broad composition patents expire. A biosimilar developer must reproduce stability, potency and impurity performance without infringing valid claims or relying on an unavailable manufacturing process.

What commercial opportunities exist for MIRCERA excipients?

High-purity excipient supply

The most immediate opportunity is supply of polysorbate 20, L-methionine, pharmaceutical-grade phosphate salts and sodium sulfate. Suppliers can differentiate through:

• Low peroxide polysorbate grades
• Lot-to-lot fatty-acid consistency
• Enhanced trace-metal control
• GMP documentation
• Global regulatory support
• Stability data in protein formulations

Excipient replacement and formulation improvement

Potential development programs include:

• Polysorbate 20 alternatives with lower oxidation liability
• Nonionic surfactants with improved syringe compatibility
• Histidine or other buffer systems
• Amino-acid antioxidant combinations
• Preservative-free presentations
• Lower-volume high-concentration formulations

Any alternative must preserve biological activity, aggregation profile, particle burden, injectability and immunogenicity performance.

Prefilled syringe and container technologies

MIRCERA’s low-volume presentation creates opportunities for:

• Low-silicone or silicone-free syringes
• Tungsten-controlled glass systems
• Polymer syringes
• Low-extractables elastomers
• Integrated needle shields
• Reduced dead-space systems
• Automated filling and inspection

Container-closure performance is particularly important for protein injectables because silicone oil, tungsten residues, elastomer components and leachables can affect particle formation and product quality.

Biosimilar development services

Contract organizations can commercialize services covering:

• Glycan and PEG-conjugate characterization
• Peptide mapping
• Aggregate and particle analysis
• Potency assays
• Forced-degradation studies
• Extractables and leachables testing
• Device compatibility
• Comparability protocol design

The analytical burden is higher than for a conventional epoetin product because the PEG modification adds molecular heterogeneity and requires specialized characterization.

What is the FDA regulatory status of MIRCERA?

MIRCERA is FDA-approved for anemia associated with chronic kidney disease in adult patients, including patients on dialysis and patients not on dialysis, subject to the product label’s limitations and dosing instructions.[2] It is administered intravenously or subcutaneously, depending on the patient population and clinical setting.

The label contains class-related warnings for erythropoiesis-stimulating agents, including risks associated with hemoglobin targets, cardiovascular events, hypertension and tumor-related outcomes. These safety considerations affect commercial positioning and can limit the value of a formulation advantage if the product does not improve the overall treatment pathway.

What is the revenue exposure and commercial outlook?

MIRCERA revenue is exposed to three forces:

1. Dialysis-center purchasing and tender pressure.
2. Substitution by other erythropoiesis-stimulating agents.
3. Biosimilar entry and price erosion.

Its long-acting profile can reduce administration frequency and nursing workload. The economic benefit is clearest in chronic kidney disease care, where treatment is delivered repeatedly and operational costs are material.

The most attractive commercial opportunities are not limited to selling the finished drug. Suppliers can capture value through excipient qualification, formulation development, device components, biosimilar analytics and regional manufacturing partnerships.

How does MIRCERA compare with competing erythropoiesis-stimulating agents?

Product	Active molecule	Dosing profile	Main competitive advantage
MIRCERA	Pegylated epoetin beta	Long-acting	Reduced dosing frequency
Epoetin alfa	Recombinant epoetin alfa	Shorter acting	Broad availability and lower-cost competition
Epoetin beta	Recombinant epoetin beta	Shorter acting	Established renal-anemia use
Darbepoetin alfa	Hyperglycosylated epoetin analog	Longer acting	Lower frequency than conventional epoetin
HIF-PH inhibitors	Small molecules	Oral	Noninjectable administration in applicable markets

MIRCERA’s formulation is optimized for a biologic that must remain stable in a small-volume liquid presentation. Competing oral products avoid some injectable excipient constraints but introduce different safety, monitoring and reimbursement issues.

What patent litigation affects MIRCERA?

The key litigation question is whether any live patent claims cover the reference molecule, PEG-conjugation process, formulation, container or dosing method in the intended launch jurisdiction. FDA approval alone does not resolve those rights.

For a biosimilar applicant, litigation exposure can arise through the BPCIA patent-exchange process, declaratory actions, infringement suits and settlement agreements. A current review should distinguish:

• Patents listed or disclosed for the reference product
• Patents asserted in litigation
• Patents found invalid or not infringed
• Patents expired before the proposed launch
• Patents covering only nonessential presentations

A settlement may permit an agreed launch date while preserving some claims or commercial restrictions. The economic value of a settlement depends on market share, price erosion and whether the biosimilar receives interchangeable status.

Key Takeaways

• MIRCERA uses a protein-focused excipient system built around polysorbate 20, phosphate buffer, sodium sulfate, L-methionine and, where applicable, phenoxyethanol.
• Polysorbate quality, oxidation control and syringe compatibility are the main excipient-control issues.
• MIRCERA is regulated as a biologic; biosimilar competition, not a conventional ANDA generic, is the relevant entry pathway.
• Core U.S. biologic exclusivity has elapsed, but formulation, manufacturing, device and method-of-use patents can still affect launch timing.
• Commercial opportunities are strongest in high-purity excipients, alternative surfactants, preservative-free delivery, prefilled syringes and biosimilar analytical services.
• A differentiated formulation can create a practical development barrier even when the active-molecule patent position has weakened.
• Dialysis-center economics, injection frequency and tender pricing will determine the commercial impact of future competitors.

FAQs

Can a biosimilar replace MIRCERA with the same excipients?

It can use the same excipients, but regulatory approval depends on demonstrating biosimilarity to the reference product. The applicant must control formulation quality and show that excipient differences do not affect clinical performance, immunogenicity or product quality.

Is polysorbate 20 the main formulation risk in MIRCERA?

It is one of the principal risks. Oxidation, hydrolysis, particle formation and interaction with the syringe system can affect stability. L-methionine, buffer composition and container materials also contribute to the overall risk profile.

Could MIRCERA be reformulated without phenoxyethanol?

A preservative-free version may be technically feasible in a single-dose container, but it would require new stability, sterility, container-closure and regulatory assessments. It would not automatically be interchangeable with the existing presentation.

Are MIRCERA excipients protected by separate patents?

Some formulation patents may claim specific combinations, concentrations or stability characteristics. The practical risk depends on the exact claim language, remaining term and jurisdiction. Excipient substitution is often possible, but the replacement must maintain product performance and avoid infringement.

What is the most valuable commercial opportunity around MIRCERA?

For suppliers, high-purity polysorbate 20 and protein-compatible container systems are the clearest opportunities. For drug developers, the strongest opportunity is a biosimilar or follow-on pegylated erythropoietin supported by robust analytical characterization and a differentiated delivery system.

References

1. European Medicines Agency. (2024). Mircera: EPAR product information. European Union.

2. U.S. Food and Drug Administration. (2024). Mircera (methoxy polyethylene glycol-epoetin beta) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

4. U.S. Food and Drug Administration. (2023). Biosimilar and interchangeable biosimilar products. FDA.